Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Advising AML patients to participate in clinical trials

Marina Konopleva • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Azacitidine Decitabine Venetoclax

The widespread accessing of new drugs by HCPs and patients can be a very long process. Currently, venetoclax is in clinical trials for acute myeloid leukemia (AML) and hence, has not yet been approved for prescription. In this interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, encourages elderly patients with AML to participate in clinical trials, such as NCT03069352, as well as acknowledging the difficulties of this. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals